Mai Anh Huynh, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 6 | 2023 | 1346 | 1.910 |
Why?
|
| Tattooing | 1 | 2023 | 57 | 0.860 |
Why?
|
| Urogenital Neoplasms | 1 | 2024 | 132 | 0.830 |
Why?
|
| Bone Diseases | 1 | 2022 | 416 | 0.620 |
Why?
|
| Neoplasm Metastasis | 3 | 2024 | 4926 | 0.610 |
Why?
|
| Prostatic Neoplasms | 5 | 2024 | 11229 | 0.550 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 3 | 2009 | 170 | 0.430 |
Why?
|
| Palliative Care | 5 | 2025 | 3644 | 0.400 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 2250 | 0.340 |
Why?
|
| Cell Shape | 1 | 2011 | 371 | 0.340 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 5 | 2025 | 1679 | 0.310 |
Why?
|
| Axons | 3 | 2009 | 1678 | 0.270 |
Why?
|
| Neoplasms | 5 | 2022 | 22390 | 0.270 |
Why?
|
| Androgen Antagonists | 3 | 2024 | 1421 | 0.260 |
Why?
|
| Nerve Tissue Proteins | 4 | 2011 | 4415 | 0.240 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 6401 | 0.230 |
Why?
|
| Cerebellum | 2 | 2011 | 1522 | 0.230 |
Why?
|
| Cadherins | 1 | 2009 | 906 | 0.230 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 1625 | 0.220 |
Why?
|
| Rats, Long-Evans | 5 | 2011 | 380 | 0.210 |
Why?
|
| Neurons | 3 | 2011 | 9524 | 0.200 |
Why?
|
| Cell Movement | 2 | 2011 | 5216 | 0.190 |
Why?
|
| Thoracic Neoplasms | 1 | 2023 | 269 | 0.190 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 8559 | 0.180 |
Why?
|
| Transcription Factors | 5 | 2014 | 12174 | 0.180 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2023 | 459 | 0.160 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2021 | 264 | 0.160 |
Why?
|
| Workflow | 1 | 2023 | 859 | 0.160 |
Why?
|
| Health Facilities | 1 | 2023 | 577 | 0.150 |
Why?
|
| Spinal Neoplasms | 2 | 2025 | 715 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2023 | 1203 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 3782 | 0.120 |
Why?
|
| Telomere | 1 | 2021 | 943 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 1156 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 1 | 2025 | 2181 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2014 | 2892 | 0.110 |
Why?
|
| Radiotherapy Dosage | 2 | 2023 | 2920 | 0.110 |
Why?
|
| Immune System | 1 | 2019 | 800 | 0.110 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 13593 | 0.110 |
Why?
|
| Disease Management | 1 | 2024 | 2537 | 0.110 |
Why?
|
| Analysis of Variance | 3 | 2011 | 6242 | 0.100 |
Why?
|
| Radiation Oncology | 1 | 2019 | 572 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 3 | 2014 | 2004 | 0.100 |
Why?
|
| Retrospective Studies | 9 | 2025 | 81892 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2019 | 1249 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 408 | 0.090 |
Why?
|
| Humans | 22 | 2025 | 768887 | 0.090 |
Why?
|
| DNA Damage | 1 | 2021 | 2472 | 0.090 |
Why?
|
| Leucovorin | 1 | 2013 | 643 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 2 | 2023 | 5443 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 12563 | 0.090 |
Why?
|
| Smad2 Protein | 2 | 2008 | 144 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2020 | 3585 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2014 | 4528 | 0.080 |
Why?
|
| Camptothecin | 1 | 2013 | 600 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 755 | 0.080 |
Why?
|
| Leupeptins | 1 | 2009 | 113 | 0.080 |
Why?
|
| Pain | 2 | 2022 | 5100 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2024 | 65485 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2025 | 54950 | 0.080 |
Why?
|
| Animals, Newborn | 3 | 2009 | 2695 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 874 | 0.080 |
Why?
|
| Morphogenesis | 2 | 2009 | 747 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2013 | 1655 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2015 | 1224 | 0.070 |
Why?
|
| Male | 9 | 2025 | 365249 | 0.070 |
Why?
|
| Rats | 5 | 2011 | 23847 | 0.070 |
Why?
|
| Propensity Score | 1 | 2015 | 1968 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2014 | 5035 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2565 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 2 | 2009 | 2067 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3951 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2011 | 19023 | 0.060 |
Why?
|
| Growth Cones | 1 | 2006 | 117 | 0.060 |
Why?
|
| Purines | 1 | 2009 | 615 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2009 | 664 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 375 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 1903 | 0.060 |
Why?
|
| Transfection | 2 | 2009 | 5763 | 0.060 |
Why?
|
| Risk | 1 | 2016 | 9621 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5434 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 859 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2011 | 11684 | 0.050 |
Why?
|
| Animals | 8 | 2019 | 169408 | 0.050 |
Why?
|
| Survival Rate | 1 | 2015 | 12873 | 0.050 |
Why?
|
| Comorbidity | 1 | 2016 | 10591 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2021 | 88 | 0.050 |
Why?
|
| Quality of Life | 2 | 2020 | 13510 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2014 | 3701 | 0.040 |
Why?
|
| RNA Helicases | 1 | 2021 | 144 | 0.040 |
Why?
|
| Protein Binding | 3 | 2021 | 9344 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 2431 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2021 | 859 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 3724 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2009 | 8317 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 2813 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 9213 | 0.040 |
Why?
|
| Spine | 1 | 2025 | 1141 | 0.040 |
Why?
|
| Death | 1 | 2022 | 683 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 3450 | 0.040 |
Why?
|
| RNA Interference | 3 | 2014 | 2835 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 997 | 0.040 |
Why?
|
| CpG Islands | 1 | 2021 | 1210 | 0.030 |
Why?
|
| Cerebellar Cortex | 2 | 2008 | 108 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2021 | 854 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2009 | 4940 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1913 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2009 | 23652 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 2525 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 11934 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 2204 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 39394 | 0.030 |
Why?
|
| Sumoylation | 1 | 2014 | 83 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 378 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2021 | 2937 | 0.030 |
Why?
|
| Aged | 4 | 2024 | 171790 | 0.030 |
Why?
|
| Mammary Glands, Animal | 1 | 2014 | 273 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 3433 | 0.020 |
Why?
|
| Middle Aged | 4 | 2024 | 223740 | 0.020 |
Why?
|
| Stents | 1 | 2023 | 3200 | 0.020 |
Why?
|
| Mutation | 2 | 2021 | 30266 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 2749 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 5801 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2020 | 3143 | 0.020 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2009 | 147 | 0.020 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2009 | 125 | 0.020 |
Why?
|
| Mink | 1 | 2008 | 31 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 74971 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2020 | 3626 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2009 | 252 | 0.020 |
Why?
|
| Cell Line | 2 | 2014 | 15603 | 0.020 |
Why?
|
| Time Factors | 1 | 2009 | 40266 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 2635 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4593 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 59738 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 1667 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 755 | 0.020 |
Why?
|
| Binding Sites | 1 | 2014 | 6023 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 930 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9442 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4291 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 17174 | 0.010 |
Why?
|
| Algorithms | 1 | 2025 | 14199 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 2006 | 796 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2006 | 1435 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6856 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 13427 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 17629 | 0.010 |
Why?
|
| Gene Expression | 1 | 2014 | 7602 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2025 | 20776 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2006 | 1564 | 0.010 |
Why?
|
| Massachusetts | 1 | 2013 | 8888 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 1320 | 0.010 |
Why?
|
| Brain | 1 | 2006 | 27476 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2006 | 2941 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 11262 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2006 | 2885 | 0.010 |
Why?
|
| Female | 3 | 2025 | 397464 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 36861 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2006 | 2986 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 7609 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2009 | 12809 | 0.010 |
Why?
|
| Adult | 2 | 2020 | 223818 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 10486 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 11886 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 82074 | 0.000 |
Why?
|